Health issues come to the fore in the context of the goals and objectives of the development of our country. According to the order of the President of the Russian Federation Vladimir Putin, by July 1, 2020, the government needs to submit methodological proposals for a pilot project. Today, at the federal level, there is no understanding of how drug reimbursement models will be implemented. There are several suggestions, but there is no final decision as to which drug reimbursement system will be implemented, and there are no legal acts.
The Ministry of Health is preparing to test the drug reimbursement system. 47 regions agreed to join the pilot; 23 drugs were identified that will participate in the experiment. It remains only to determine the model and approve all the nuances at the legislative level.
“There is a pilot project that was implemented in Kirov, it’s not perfect, but it is an experience and should be considered when determining the final model of drug reimbursement,” said Victor Dmitriev, Director General of the Association of Russian Pharmaceutical Manufacturers.
Pilot projects on drug reimbursement, the availability of drug insurance is one of the leading topics of discussion at the conference “State regulation and the pharmaceutical industry: the continuation of the dialogue”, which will be held on April 7 at the World Trade Center.
The conference is an authoritative platform for the exchange of experience in the field of the healthcare system, discussion of current issues and problems.
Annually, the conference summarizes and determines the prospects for the development of the pharmaceutical industry and healthcare in general.
The growing number of conference participants every year proves the interest of professionals in the selected format.
Ramil Khabriev, Academician of the Russian Academy of Sciences, Scientific Director of the “National Research Institute of Public Health named after N.A. Semashko” believes that the protection of health and health maintenance have become the main guidelines in the social policy of the state. The indicators indicated for national purposes to reduce mortality and increase life expectancy dictate the need for a serious review of priorities in the system of medical care for the population. ”
“The general euphoria about the growth rate of the high-tech types of medical care was not able to offset the obvious omissions in the availability and quality of its provision in primary care. I would like to hope that the correction of the situation will not be reduced only to the construction, repair and equipment of medical facilities and clinics. One of the most important components of the accessibility and quality of medical care is the provision of medicines. The seriousness of this problem can be judged by the President’s of the country and the Head’s of Government participation in dealing with it. And these are the consequences of years of delayed reform of drug provision in outpatient treatment. Maybe we will start this year?” Ramil Khabriev emphasized.
The conference will be attended by representatives of federal and regional specialized ministries, heads of state and private medical institutions, regional departments, health departments, pharmaceutical companies, the scientific and expert community.
ARPM General Director Victor Dmitriev recalled that the Association initiated this annual conference 12 years ago. This proposal was immediately supported by the Ministry of Health of Russia, Federal Service for Surveillance in Healthcare (Roszdravnadzor), the Ministry of Industry and Trade, heads of pharmaceutical enterprises and industry experts.
On April 7, 2020, the World Trade Center will host the main industry scientific-practical conference "State regulation and the Russian pharmaceutical industry 2020: the continuation of the dialogue." The conference program includes issues of the availability of drugs and the selection of optimal mechanisms for implementing the drug reimbursement system, the availability of drug insurance, quality control in the field of drug circulation: reality and prospects. Implementation of legislative initiatives: interchangeability, regulatory guillotine, labeling. The focus is on the global challenges and guidelines for the development of the pharmaceutical industry. Investment attractiveness, export potential. Support tools for the development of the Russian pharmaceutical industry. Analytical review and forecast of the development of the pharmaceutical market.